Barclays lowered the firm’s price target on BioMarin to $111 from $125 and keeps an Overweight rating on the shares. The company reported a Q3 Roctavian miss with 2023 guidance cut, the analyst tells investors in a research note. The firm expects uptake will likely picking up in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMRN:
- BioMarin names Alexander Hardy CEO, succeeding Jean-Jacques Bienaime
- BioMarin narrows 2023 non-GAAP EPS $1.90-$2.05 from $1.85-$2.10, consensus $1.02
- BioMarin reports Q3 non-GAAP EPS 46c, consensus 22c
- BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
- Notable companies reporting after market close